Inhaled insulin

British Medical Journal

Volumn 332, Issue 7549, 2006, Pages 1043-1044

  Morton Eggleston, Emma ^a   Barrett, Eugene J ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EXENDIN 4; INSULIN; PRAMLINTIDE; ANTIDIABETIC AGENT;

CLINICAL TRIAL; COST BENEFIT ANALYSIS; DRUG APPROVAL; DRUG EFFICACY; DRUG FORMULATION; DRUG TOLERABILITY; EDITORIAL; EXERCISE; FOLLOW UP; GLYCEMIC CONTROL; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT SATISFACTION; PRIORITY JOURNAL; UNSPECIFIED SIDE EFFECT; DIABETES MELLITUS; INHALATIONAL DRUG ADMINISTRATION;

ADMINISTRATION, INHALATION; DIABETES MELLITUS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN;

EID: 33646490604     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.332.7549.1043     Document Type: Editorial

References (13)

1. Garg S, Rosenstock J, Silverman BL, Sun B, Konkoy CS, de la Pena A, et al. Efficacy and safety of preprandial human insulin inhalation powder versus injectable insulin in patients with type 1 diabetes. Diabetologia 2006 (in press).
2. Edgerton DS, Neal DW, Scott M, Bowen L, Wilson W, Hobbs CH, et al. Inhalation of insulin (Exubera) is associated with augmented disposal of portally infused glucose in dogs. Diabetes 2005;54:1164-70.
3. Quattrin T, Belanger A, Bohannon NJ, Schwartz SL. Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 1 diabetes: results of a 6-month, randomized, comparative trial. Diabetes Care 2004;27:2622-7.
4. Skyler JS, Weinstock RS, Raskin P, Yale JF, Barrett E, Gerich JE, et al. Use of inhaled insulin in a basal/bolus insulin regimen in type 1 diabetic subjects: a 6-month, randomized, comparative trial. Diabetes Care 2005;28:1630-5.
5. DeFronzo RA, Bergenstal RM, Cefalu WT, Pullman J, Lerman S, Bode BW, et al. Efficacy of inhaled insulin 'in patients with type 2 diabetes not controlled with diet and exercise: a 12-week, randomized, comparative trial. Diabetes Care 2005;28:1922-8.
6. Cefalu WT, Skyler JS, Kourides IA, Landschulz WH, Balagtas CC, Cheng S, et al. Inhaled human insulin treatment in patients with type 2 diabetes mellitus. Ann Intern Med 2001;134:203-7.
7. Weiss SR, Cheng SL, Kourides IA, Gelfand RA, Landschulz WH. Inhaled insulin provides improved glycemic control in patients with type 2 diabetes mellitus inadequately controlled with oral agents: a randomized controlled trial. Arch Intern Med 2003;163:2277-82.
8. Fineberg SE, Kawabata T, Finco-Kent D, Liu C, Krasner A. Antibody response to inhaled insulin in patients with type 1 or type 2 diabetes. An analysis of initial phase II and III inhaled insulin (Exubera) trials and a two-year extension trial. J Clin Endocrinol Metab 2005;90:3287-94.
9. Teeter JG, Riese RJ. Dissociation of lung function changes with humoral immunity during inhaled human insulin therapy. Am J Respir Crit Care Med 2006 (in press). http://ajrccm.atsjournals.org/cgi/reprint/200512-1861OCv1 (accessed 27 Apr 2006).
10. Rosenstock J, Cappelleri JC, Bolinder B, Gerber RA. Patient satisfaction and glycemic control after 1 year with inhaled insulin (Exubera) in patients with type 1 or type 2 diabetes. Diabetes Care 2004;27:1318-23.
11. Gerber RA, Cappelleri JC, Kourides IA, Gelfand RA. Treatment satisfaction with inhaled insulin in patients with type 1 diabetes: a randomized controlled trial. Diabetes Care 2001;24:1556-9.
12. Cappelleri JC, Cefalu WT, Rosenstock J, Kourides IA, Gerber RA. Treatment satisfaction in type 2 diabetes: a comparison between an inhaled insulin regimen and a subcutaneous insulin regimen. Clin Ther 2002;24:552-64.
13. National Institute for Health and Clinical Excellence. Inhaled insulin for the treatment of diabetes (types 1 and 2): appraisal consultation documents. 2006. www.nice.org.uk/page.aspx?o = 305474 (accessed 24 April).